Natasha Kyprianou, PhD Email Natasha Kyprianou
- PROFESSOR | Urology
- PROFESSOR | Oncological Sciences
- PROFESSOR | Pathology, Molecular and Cell Based Medicine
Dr. Natasha Kyprianou is a Professor in the Departments of Urology and Oncological Sciences at the Icahn School of Medicine at Mount Sinai and a member of the NCI-designated Tisch Cancer Institute. Dr. Kyprianou is a translational researcher in urologic oncology with expertise in the pathobiology of prostate, bladder and kidney cancer and specific focus on dissecting mechanisms of therapeutic resistance in advanced lethal disease. Pioneering studies by Dr. Kyprianou’s team first established the novel effect of microtubule-targeting chemotherapy on the localization of the androgen receptor (AR) and activity in prostate cancer enabling a novel insight into therapeutic cross-resistance. This paradigm shift evidence fueled a new direction of investigations in therapeutic targeting of AR by taxane chemotherapys. More recent studies using pre-clinical models and prostate cancer xenografts exploited the therapeutic targeting of epithelial-mesenchymal transition (EMT) in metastatic castration resistant prostate cancer (CRPC) by taxane chemotherapy, in combination with antiandrogens. In pursuing apoptosis-inducing therapeutics against advanced urologic tumors, Dr. Kyprianou and her group found that drugs used to treat benign prostatic hyperplasia, α1-adrenoceptor antagonists such as doxazosin and terazosin (harboring the quinazoline-structural nucleus) have novel apoptosis-inducting activity in benign and malignant prostate tissue. Structural optimization led to the discovery of a novel class of quinazoline-based compounds with potent anoikis-inducing effects against prostate and renal tumors. Further functional characterization of lead quinazoline compounds identified the molecular profiling of anoikis-inducing effect against tumor growth, vascularity and metastasis via targeting ECM interactions and focal adhesions in in vitro and in vivo, models of CRPC and renal cancer.
Apoptosis/Cell Death, Cancer, Cell Adhesion, Cellular Differentiation, Cytoskeleton, Intracellular Transport, Metastasis, Microtubules, Oncogenes, Prostate, Protein Trafficking & Sorting, Receptors, Translational Research, Tumor Suppressor Genes, Tumorigenesis
EnglishDownload the CV
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Kyprianou has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.